​

Edesa Biotech Stock (NASDAQ:EDSA)

OwnershipFinancialsChart
Edesa Biotech by TradingView

Previous Close

$1.44

52W Range

$1.28 - $4.49

50D Avg

$1.58

200D Avg

$2.08

Market Cap

$10.36M

Avg Vol (3M)

$58.78K

Beta

0.14

Div Yield

-

EDSA Company Profile

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

16

IPO Date

Jun 21, 2010

Website

EDSA Performance

EDSA Financial Summary

Sep 24Sep 23Sep 22
Revenue---
Operating Income$-7.01M$-9.22M$-18.37M
Net Income$-6.17M$-8.37M$-17.55M
EBITDA$-5.98M$-8.19M$-17.43M
Basic EPS$-1.93$-2.93$-8.37
Diluted EPS$-1.93$-2.93$-8.37

Fiscal year ends in Sep 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 16Dec 15, 16 | 1:30 PM
Q3 16Aug 10, 16 | 1:30 PM
Q2 16May 11, 16 | 1:30 PM

Peer Comparison

TickerCompany
OSRHOSR Holdings, Inc.
ERNAErnexa Therapeutics Inc.
BRTXBioRestorative Therapies, Inc.
DWTXDogwood Therapeutics, Inc.
SNSESensei Biotherapeutics, Inc.
EVGNEvogene Ltd.
COCPCocrystal Pharma, Inc.
IMRNImmuron Limited
IMNNImunon, Inc.
TRAWTraws Pharma, Inc.